[Comment on: "Lack of insight in schizophrenia: a review. Part I: theoretical concept, clinical aspects and Amador's model" of S. Raffard, S. Bayard, D., Capdevielle, F. Garcia, J.-P. Boulenger et M.-C. Gely-Nargeot].
Caillard
V
V
D014150:Antipsychotic Agents / Q000627:therapeutic use; D001364:Awareness; D001569:Benzodiazepines / Q000627:therapeutic use; D015897:Comorbidity; D003430:Cross-Sectional Studies; D006801:Humans; D000077152:Olanzapine; D011379:Prognosis; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology; D012565:Schizophrenic Psychology; D013405:Suicide / Q000523:psychology / Q000706:statistics & numerical data; D013406:Suicide, Attempted / Q000517:prevention & control / Q000523:psychology / Q000706:statistics & numerical data; D014754:Violence / Q000517:prevention & control / Q000523:psychology / Q000706:statistics & numerical data; D000092864:Suicide Prevention
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine